Francis, A, Fallowfield, L and Rea, D (2015) The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clinical Oncology, 27 (1). pp. 6-8. ISSN 0936-6555

Full text not available from this repository.

Abstract

An unforeseen consequence of the introduction of mammographic breast screening has been the marked increase in the number of women diagnosed with ductal carcinoma in situ (DCIS) [1,2]. In 2009–2010, 2830 women were diagnosed with in situ carcinoma through the National Health Service Breast Screening Programme (NHSBSP) [3]. Screen-detected DCIS now accounts for 20% of ‘cancers’ identified through breast screening. However, the intent of breast screening programmes was to detect early invasive cancer, not to identify DCIS.

Item Type:	Article
Schools and Departments:	Brighton and Sussex Medical School > Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Subjects:	R Medicine > RC Internal medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens > RC0280 By region, system, or organ of the body, or type of tumor, A-Z > RC0280.B8 Breast. Mammary glands
Depositing User:	Kathryn Monson
Date Deposited:	15 Dec 2014 15:03
Last Modified:	01 Jun 2015 15:01
URI:	http://sro.sussex.ac.uk/id/eprint/51696

📧 Request an update